Literature DB >> 3480885

Decrease of caffeine elimination in man during co-administration of 4-quinolones.

W Stille1, S Harder, S Mieke, C Beer, P M Shah, K Frech, A H Staib.   

Abstract

The single dose pharmacokinetics of caffeine (220-230 mg per dose) were investigated in 12 healthy male volunteers before and during treatment with ofloxacin (200 mg bd), ciprofloxacin (250 mg bd) and enoxacin (400 mg bd) with a cross-over study design. None of the parameters: mean elimination half-life (T1/2el), Cmax, total body clearance (Cltot) and the volume of distribution (aVd) of caffeine were noticeably altered by administration of ofloxacin. Striking changes were observed, however, after administration of enoxacin: the T1/2el was prolonged by as much as 260%, the Cmax increased by 41%; the aVd was reduced by 20% and Cltot by 78% (mean values). Treatment with ciprofloxacin led to a prolongation of T1/2el by 15%, to a decrease of aVd by 25% and to a 33% decrease of Cltot. The results of this intra-individual comparison of caffeine pharmacokinetic data demonstrate that treatment with ciprofloxacin and enoxacin may have a significant inhibitory effect on caffeine elimination.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3480885     DOI: 10.1093/jac/20.5.729

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  In vivo and in vitro toxicodynamic analyses of new quinolone-and nonsteroidal anti-inflammatory drug-induced effects on the central nervous system.

Authors:  H Kita; H Matsuo; H Takanaga; J Kawakami; K Yamamoto; T Iga; M Naito; T Tsuruo; A Asanuma; K Yanagisawa; Y Sawada
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

3.  Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients.

Authors:  M H Chandler; S M Toler; R P Rapp; R R Muder; J A Korvick
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

4.  Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Authors:  Laurence Gabriel; Michel Tod; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

5.  Lack of interaction between lomefloxacin and caffeine in normal volunteers.

Authors:  D P Healy; J R Schoenle; J Stotka; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 6.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 7.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

8.  The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.

Authors:  V Spaldin; S Madden; W F Pool; T F Woolf; B K Park
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

9.  PK-DB: pharmacokinetics database for individualized and stratified computational modeling.

Authors:  Jan Grzegorzewski; Janosch Brandhorst; Kathleen Green; Dimitra Eleftheriadou; Yannick Duport; Florian Barthorscht; Adrian Köller; Danny Yu Jia Ke; Sara De Angelis; Matthias König
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971

10.  4-quinolones inhibit biotransformation of caffeine.

Authors:  S Harder; A H Staib; C Beer; A Papenburg; W Stille; P M Shah
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.